These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 35613827)

  • 1. Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.
    Ellingsen EB; Aamdal E; Guren T; Lilleby W; Brunsvig PF; Mangsbo SM; Aamdal S; Hovig E; Mensali N; Gaudernack G; Inderberg EM
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35613827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
    Aamdal E; Inderberg EM; Ellingsen EB; Rasch W; Brunsvig PF; Aamdal S; Heintz KM; Vodák D; Nakken S; Hovig E; Nyakas M; Guren TK; Gaudernack G
    Front Immunol; 2021; 12():663865. PubMed ID: 34046035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
    Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM
    Front Immunol; 2020; 11():572172. PubMed ID: 33324397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
    Ellingsen EB; Bounova G; Kerzeli I; Anzar I; Simnica D; Aamdal E; Guren T; Clancy T; Mezheyeuski A; Inderberg EM; Mangsbo SM; Binder M; Hovig E; Gaudernack G
    J Transl Med; 2022 Sep; 20(1):419. PubMed ID: 36089578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.
    Lilleby W; Gaudernack G; Brunsvig PF; Vlatkovic L; Schulz M; Mills K; Hole KH; Inderberg EM
    Cancer Immunol Immunother; 2017 Jul; 66(7):891-901. PubMed ID: 28391357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model.
    Ibrahim EIK; Ellingsen EB; Mangsbo SM; Friberg LE
    Int Immunopharmacol; 2024 Jan; 126():111225. PubMed ID: 37988911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
    Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
    J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring.
    Lilleby W; Seierstad T; Inderberg EM; Hole KH
    Int J Cancer; 2023 May; 152(10):2166-2173. PubMed ID: 36715014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer.
    Brunsvig PF; Aamdal S; Gjertsen MK; Kvalheim G; Markowski-Grimsrud CJ; Sve I; Dyrhaug M; Trachsel S; Møller M; Eriksen JA; Gaudernack G
    Cancer Immunol Immunother; 2006 Dec; 55(12):1553-64. PubMed ID: 16491401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic cancer vaccination against telomerase: clinical developments in melanoma.
    Ellingsen EB; Bjørheim J; Gaudernack G
    Curr Opin Oncol; 2023 Mar; 35(2):100-106. PubMed ID: 36700456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms.
    Zareian N; Eremin O; Pandha H; Baird R; Kwatra V; Funingana G; Verma C; Choy D; Hargreaves S; Moghimi P; Shepherd A; Lobo DN; Eremin J; Farzaneh F; Kordasti S; Spicer J
    Exp Biol Med (Maywood); 2024; 249():10021. PubMed ID: 38463391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.
    Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM
    Front Immunol; 2018; 9():2145. PubMed ID: 30283461
    [No Abstract]   [Full Text] [Related]  

  • 14. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
    Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
    Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
    Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
    Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S
    Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
    Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
    J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001.
    Vetsika EK; Konsolakis G; Aggouraki D; Kotsakis A; Papadimitraki E; Christou S; Menez-Jamet J; Kosmatopoulos K; Georgoulias V; Mavroudis D
    Cancer Immunol Immunother; 2012 Feb; 61(2):157-168. PubMed ID: 21858533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
    De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial.
    Schuhmacher J; Heidu S; Balchen T; Richardson JR; Schmeltz C; Sonne J; Schweiker J; Rammensee HG; Thor Straten P; Røder MA; Brasso K; Gouttefangeas C
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33184050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.